SSNRI - Selective Serotonin Norepinephrine Reuptake Inhibitor

Information Regarding A New Class of Anti-Depressants That Act on Both Primary Neurotransmitters Serotonin and Norepinephrine

(Welcome to General SSNRI Antidepressant Information)

The most effective antidepressants work by inhibiting the reuptake of neurotransmitters in the synapse between nerve endings.  Depression has been linked primarily to a lack of specific neurotransmitters within the synapse normally through an inability to manufacture enough neurotransmitters.  The way the most common antidepressants work is to inhibit the reuptake of these neurotransmitters back into the nerves, effectively leaving them in the synapse for increased effect on the receptor sites on the receiving nerve endings.

The neurotransmitter serotonin has long been promoted as the primary neurotransmitter linked to the primary symptoms of depression and thus it has been the primary focus of all drugs aimed at helping the disease state of depression.

But it has also long been revealed that another neurotransmitter is also a very important aspect in persons suffering from depression... and that neurotransmitter is Norepinephrine.  

SSNRI Antidepressants Become a Method of Treatment

Scientists have been trying to figure out how best to implement both neurotransmitters in treating depression which led them to clinical trials and studies involving newer drugs that act on both.  The result was the first of a new class called Selective Serotonin Reuptake Inhibitors (SSNRI)s.  

SSNRI's effectively target both neurotransmitters and have a better therapeutic profile including efficacy and side effects.

SSNRI Anti-Depressants